Genprex, Inc. (GNPX)
$1.4
-0.05 (-3.45%)
Rating:
Recommendation:
-
| Symbol | GNPX |
|---|---|
| Price | $1.4 |
| Beta | -0.627 |
| Volume Avg. | 0.15M |
| Market Cap | 67.058M |
| Shares () | - |
| 52 Week Range | 1.17-3.62 |
| 1y Target Est | - |
| DCF Unlevered | GNPX DCF -> | |
|---|---|---|
| DCF Levered | GNPX LDCF -> | |
| ROE | -44.00% | Strong Sell |
| ROA | -47.78% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 6.44% | Neutral |
| P/E | - | |
| P/B | 1.81 | Strong Buy |
Latest GNPX news
About
Download (Excel)Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.